

High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection

Andrea Vianello ,¹ Giovanna Arcaro,² Beatrice Molena,² Cristian Turato,³ Andi Sukthi,² Gabriella Guarnieri,² Francesca Lugato,² Gianenrico Senna,⁴ Paolo Navalesi⁵

¹Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy

²Department of Cardiac, Thoracic and Vascular Sciences, University-City Hospital of Padova, Padova, Italy

³Department of Molecular Medicine, University of Pavia, Pavia, Italy

⁴Department of Medicine, University of Verona, Verona, Italy

⁵Department of Medicine DIMED, University of Padova, Padova, Italy

Correspondence to

Professor Andrea Vianello, -, Padova 35128, Italy; andrea.vianello@aopd.veneto.it

Received 14 April 2020
Revised 26 June 2020
Accepted 27 June 2020
Published Online First
23 July 2020

ABSTRACT

This observational study aims to assess the outcome and safety of O₂-therapy by high-flow nasal cannula (HFNC) in 28 consecutive patients with severe hypoxemic acute respiratory failure (hARF) consequent to SARS-CoV-2 infection, unresponsive to conventional O₂-therapy. Nineteen patients had a positive response. Nine patients required escalation of treatment to non-invasive ventilation (five subsequently intubated). None of the staff had a positive swab testing during the study period and the following 14 days. Severity of hypoxemia and C reactive protein level were correlated with HFNC failure. These data suggest HFNC to be a safe treatment for less severe patients with SARS-CoV-2 hARF and efficacy will need to be assessed as part of a clinical trial.

Patients with Coronavirus 2 (SARS-CoV-2) infection may experience severe hypoxemic acute respiratory failure (hARF) requiring supportive respiratory therapy.¹

O₂-therapy by high-flow nasal cannula (HFNC), which allows delivering heated, humidified inspired gas at a high flow rate and precise fraction of inspired oxygen (FiO₂), has been increasingly used in patients with severe hARF.² Recent guidelines for the management of SARS-CoV-2 infection suggest HFNC also for treatment of SARS-CoV-2 hARF unresponsive to conventional O₂-therapy.³ However, data on the efficacy of HFNC in these patients are scarce and there are major concerns on the possibility of spreading infection among health-care personnel caring for patients in SARS-CoV-2 dedicated areas.

We report the outcomes of 28 consecutive unselected patients with hARF admitted to the SARS-CoV-2 Respiratory Intensive Care Unit (RICU) of the University Hospital of Padua between 13 and 23 March 2020 who underwent HFNC. The criterion for patients' admission to our RICU was failure of conventional O₂-therapy to maintain SaO₂ ≥92%. Study ethical approval was waived by the local Ethics Committee in view of the fact that all the procedures being performed were part of the routine care.

Study inclusion criteria were (1) laboratory-confirmed COVID-19 infection⁴; (2) PaO₂/F_iO₂ ratio <300 mmHg, F_iO₂ being determined as previously described⁵; (3) failure of conventional O₂-therapy delivered through a non-rebreathing mask with a reservoir bag to maintain SaO₂

≥92%. Exclusion criteria were need for immediate endotracheal intubation (ETI) and haemodynamic instability.

A treatment algorithm from the hospital internal protocol based on a stepwise utilisation of HFNC, non-invasive ventilation (NIV) and ETI was used in the effort to reverse hypoxemia in these patients (figure 1). HFNC oxygen therapy was delivered using an AIRVO2 respiratory humidifier (Fisher & Paykel Healthcare, Auckland, New Zealand), with an integrated flow generator able to adjust F_iO₂ (between 0.21 and 1.0) and to deliver an air/oxygen mixture at flow rates of up to 60 L/min. The gas mixture (at 37°C) is routed through a circuit via large-bore bi-nasal prongs.

HFNC was initially used at a 60 L/min gas flow rate and a F_iO₂ of 1.0; it was then adjusted to provide the minimum F_iO₂ necessary to maintain a SaO₂ ≥92%. To reduce the risk of viral transmission, the patient wore a surgical mask and was instructed to breathe through a closed mouth as long as possible.

The patients were divided into two groups depending on their outcome: the first (success group) included patients who had a successful outcome, as defined by reversal of hypoxemia (SaO₂ ≥92%), no need for NIV and/or invasive mechanical ventilation (IMV), discharge from RICU, with the patient alive and conscious for at least 48 hours after discharge. The second group (failure group) included patients who had an unsuccessful outcome, defined as the need for NIV or IMV by ETI and/or death while on HFNC support.

The patients' baseline demographic and clinical features and clinical and laboratory data at RICU admission (also including SOFA score⁶) are outlined in table 1. Arterial blood gases were obtained while patients were receiving supplemental oxygen therapy via non-rebreathing mask with a reservoir bag.

The male:female ratio was 3 to 1 (21 vs 7). The patients were classified, in accordance with the WHO criteria,⁴ as showing moderate (17 cases) or severe (11 cases) acute respiratory distress at the time they were admitted to the RICU.

Nineteen (67.8%) succeeded HFNC as hypoxemia was reversed and they were discharged from the RICU and were still alive on day 15 after discharge. Nine patients (32.2%) failed HFNC and received NIV. Five of them (17.8%) subsequently required IMV, of whom three died. All nine failing



© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Vianello A, Arcaro G, Molena B, et al. *Thorax* 2020;**75**:998–1000.






Figure 1 Treatment algorithm. HFNC, high-flow nasal cannula; NIV, non-invasive ventilation; RR, respiratory rate; SaO₂, arterial oxygen saturation.

patients had lower PaO₂/F₁O₂ (76 (53–190) vs 126 (52–296) mmHg; p=0.0194) and higher serum C reactive protein level (130 (110–270) vs 110 (29–180); p=0.01277) with respect to their counterparts. Exact logistic regression following

multivariate analysis indicated PaO₂/F₁O₂ to be significantly associated with treatment failure (p=0.0314). Patients with PaO₂/F₁O₂ at RICU admission ≤100 mmHg showed a greater rate of treatment failure (7/9 (77.8%)), as opposed to those with PaO₂/

Table 1 Patients' baseline demographic and clinical characteristics, and clinical and laboratory data at RICU admission

	All cases (n=28)	Success group (n=19)	Failure group (n=9)	P value
Clinical and demographic features				
Age (years), median (min–max)	69 (42–87)	67 (42–84)	80 (64–87)	0.0543
Gender (males/females)	21/7	13/6	8/1	0.2513
No of smokers	6 (21.4%)	3 (15.7%)	3 (33.3%)	0.2995
No of patients with comorbidities	20 (71.4%)	13 (68.4%)	7 (77.8%)	0.5286
No of comorbidities per patient, median (min–max)	1 (0–4)	1 (0–4)	2 (0–4)	0.3922
Clinical and laboratory data at RICU admission				
Respiratory rate (breaths/min), median (min–max)	26 (12–40)	24 (12–40)	26 (15–36)	0.6950
Heart rate (beats/min), median (min–max)	77 (59–105)	77 (59–89)	77.5 (62–150)	0.6362
No of patients with fever (temperature >38°C)	11 (21.4%)	6 (31.6%)	5 (55.6%)	0.2770
No of patients with leucopenia (WBC <4400×10 ⁶ /L)	3 (10.7%)	3 (15.7%)	0 (0%)	0.2154
PaO ₂ (mm Hg), median (min–max)	57 (36.2–67.1)	58.3 (36.2–67.1)	55.5 (39.9–61)	0.1224
PaCO ₂ (mm Hg), median (min–max)	32 (27–45)	31.9 (28–45)	32.9 (27–39)	0.9115
Arterial pH, median (min–max)	7.48 (7.39–7.54)	7.49 (7.39–7.52)	7.47 (7.40–7.54)	0.9357
SaO ₂ (%), median (min–max)	92 (79–97)	93 (79–97)	90 (79–94)	0.0293
FiO ₂ , median (min–max)	0.6 (0.4–1.0)	0.6 (0.4–1.0)	0.8 (0.6–1.0)	0.0085
PaO ₂ /FiO ₂ (mm Hg), median (min–max)	108 (52–296)	126 (52–296)	76 (53–190)	0.0194
No of patients with PaO ₂ /FiO ₂ ≤100	13 (46.4%)	6 (31.6%)	7 (77.8%)	0.0246
D-dimer (ng/mL), median (min–max)	444 (159–259)	327 (168–759)	727 (159–259)	0.1985
Serum CRP (µg/mL), median (min–max)	110 (29–270)	110 (29–180)	130.0 (110–270)	0.0277
Ferritin (ng/mL), median (min–max)	1465.5 (156–5292)	1399.5 (156–5292)	1465.5 (877–1999)	1.000
SOFA score, median (min–max)	2 (2–4)	2 (2–4)	3 (2–3)	0.4610

P values refer to differences between HFNC success and HFNC failure groups.

CRP, C reactive protein; HFNC, high-flow nasal cannula; PaO₂/FiO₂, arterial oxygen tension to inspired oxygen fraction ratio; SaO₂, arterial oxygen saturation; SOFA, sequential organ failure assessment.

$F_{I}O_2 > 100$ mmHg (6/21 (31.6%); $p=0.0246$), with an OR of failure of 7.6 (95% CI 1.2 to 48.1).

Seventy-three healthcare workers (HCWs) (20 physicians, including residents, 40 nurses and 13 healthcare assistants) were exposed to confirmed cases of SARS-CoV-2 during the study period. Exposure duration was 48 (44–52) hours per person. All HCWs wore appropriate personal protective equipment, including gowns, hair covers, gloves, eye and face shields, and filtering face-piece respirator class 2 (FFP2) or 3 (FFP3), depending on the kind of manoeuvre performed, FFP3 being reserved for intubation, suctioning and bronchoscopy. All HCWs underwent nasopharyngeal swab on a weekly basis. HCWs who had fever or other COVID-19 signs and symptoms were immediately tested. COVID-19 swab PCR testing were negative in all our staff members during the study period and the following 14 days.

Our data suggest that HFNC played an important role in reversing hypoxemia in approximately two-thirds of the patients with SARS-CoV-2 with severe hARF unable to achieve $SaO_2 \geq 92\%$ under standard oxygen therapy. This improvement in oxygenation might depend on varied mechanisms, such as matching of delivered flow with increased ventilatory demand, achievement of high and stable $F_{I}O_2$ (up to 100%), upper airway washout, generation of positive pressure at end-expiration, and delivery of air heated and humidified.⁷ Noteworthy, $PaO_2/F_{I}O_2$ at RICU admission had prognostic relevance. In fact, in keeping with previous work,¹ patients with $PaO_2/F_{I}O_2$ values ≤ 100 mmHg had an increased risk of treatment failure.

Despite the use of HFNC as a means of respiratory support raises concerns for the increased risk of viral transmission,⁸ COVID-19 swab PCR testing resulted to be negative in all our staff members throughout the whole study period and in the following 14 days. In support of a limited risk of airborne transmission, recent data demonstrated the dispersion distance of exhaled gases during HFNC treatment to be quite limited.⁹ Worth remarking, we always applied a surgical mask over the nose and mouth of patients receiving HFNC.

Our study has limitations, such as the low number of patients enrolled and its retrospective nature, which may have caused a significant bias.

Despite these clear limitations, our data show that HFNC can

be considered an effective and safe means to improve oxygenation in less severe forms of hARF secondary to COVID-19 not responding to conventional oxygen therapy.

Contributors AV: study design, manuscript preparation. BM: data collection and analysis. CT: data collection and analysis. GA: data collection, conduction of the study. AS: conduction of the study. GG: data collection, conduction of the study. FL: data collection, conduction of the study. GS: study design, data analysis. PN: manuscript preparation, revision of the paper.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD

Andrea Vianello <http://orcid.org/0000-0002-8790-6029>

REFERENCES

- 1 Yang X, Yu Y, Xu J, *et al*. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8:475–81.
- 2 Nishimura M. High-flow nasal cannula oxygen therapy in adults. *J Intensive Care* 2015;3:15.
- 3 Alhazzani W, Mh M, Arabi YM, *et al*. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Intensive Care Med*;28.
- 4 WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. *Interim Guidance* 2020.
- 5 Branson RD, Hess DR, Chatburn RL. *Respiratory care equipment*. Philadelphia: J.B. Lippincott Company, 1995: 55–62.
- 6 Vincent JL, de Mendonça A, Cantraine F, *et al*. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. *Crit Care Med* 1998;26:1793–800.
- 7 Spoletini G, Alotaibi M, Blasi F, *et al*. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. *Chest* 2015;148:253–61.
- 8 Cheung JC-H, Ho LT, Cheng JV, *et al*. Staff safety during emergency airway management for COVID-19 in Hong Kong. *Lancet Respir Med* 2020;8:e19.
- 9 Hui DS, Chow BK, Lo T, *et al*. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. *Eur Respir J* 2019;53. doi:10.1183/13993003.02339-2018. [Epub ahead of print: 11 Apr 2019].